tetano
Editor, Senior Moderator
J Clin Neurosci
. 2023 Nov 10:118:168-174.
doi: 10.1016/j.jocn.2023.09.005. Online ahead of print. The effect of donepezil hydrochloride on post-COVID memory impairment: A randomized controlled trial
Parham Pooladgar[SUP] 1 [/SUP], Mehdi Sakhabakhsh[SUP] 2 [/SUP], Saeed Soleiman-Meigooni[SUP] 3 [/SUP], Arsia Taghva[SUP] 4 [/SUP], Malihe Nasiri[SUP] 5 [/SUP], Ilad Alavi Darazam[SUP] 6 [/SUP]
Affiliations
Background: Post-Coronavirus Disease (COVID-19) condition, known as "post-COVID syndrome," is associated with a range of complications persisting even after recovery. Among these complications, cognitive dysfunction, including memory impairment, has been relatively common observed, impacting executive function and quality of life. To date, no approved treatment exists for this specific complication. Therefore, the present clinical trial aimed to investigate the impact of Donepezil Hydrochloride on post-COVID memory impairment.
Methods: A randomized, controlled trial (Approval ID: IRCT20210816052203N1) was conducted, enrolling 25 patients with post-COVID memory impairment. Participants with a history of hospitalization were randomly assigned to either the drug group (n = 10) or the control group (n = 15). Memory indices were assessed at baseline, one month, and three months later using the Wechsler Memory Scale-Revised test. SPSS software and appropriate statistical tests were employed for data analysis.
Results: The statistical analysis revealed no significant difference in WMS-R subtest and index scores between the drug and control groups at the 4-week and 12-week follow-up periods. However, within the drug group, there was a notable increase in the visual reproduction I and verbal paired associates II subtests during the specified time intervals.
Conclusion: While donepezil 5 mg did not exhibit a significant overall increase in memory scales compared to the control group over time, our findings suggest that this medication may exert a positive effect on specific memory subtests. Further research and exploration are warranted to better understand the potential benefits of donepezil in managing post-COVID-related memory impairment.
Trial registration: The study was approved by the Research Ethics Committee of Aja University of Medical Sciences (Approval ID: IR.AJAUMS.REC.1400.125) and registered in the Iranian Registry of Clinical Trials (IRCT) (Approval ID: IRCT20210816052203N1).
Keywords: Cognitive impairment; Donepezil Hydrochloride; Long-COVID; Memory Deficit; Post-acuteCOVIDsyndrome.
. 2023 Nov 10:118:168-174.
doi: 10.1016/j.jocn.2023.09.005. Online ahead of print. The effect of donepezil hydrochloride on post-COVID memory impairment: A randomized controlled trial
Parham Pooladgar[SUP] 1 [/SUP], Mehdi Sakhabakhsh[SUP] 2 [/SUP], Saeed Soleiman-Meigooni[SUP] 3 [/SUP], Arsia Taghva[SUP] 4 [/SUP], Malihe Nasiri[SUP] 5 [/SUP], Ilad Alavi Darazam[SUP] 6 [/SUP]
Affiliations
- PMID: 37952347
- DOI: 10.1016/j.jocn.2023.09.005
Background: Post-Coronavirus Disease (COVID-19) condition, known as "post-COVID syndrome," is associated with a range of complications persisting even after recovery. Among these complications, cognitive dysfunction, including memory impairment, has been relatively common observed, impacting executive function and quality of life. To date, no approved treatment exists for this specific complication. Therefore, the present clinical trial aimed to investigate the impact of Donepezil Hydrochloride on post-COVID memory impairment.
Methods: A randomized, controlled trial (Approval ID: IRCT20210816052203N1) was conducted, enrolling 25 patients with post-COVID memory impairment. Participants with a history of hospitalization were randomly assigned to either the drug group (n = 10) or the control group (n = 15). Memory indices were assessed at baseline, one month, and three months later using the Wechsler Memory Scale-Revised test. SPSS software and appropriate statistical tests were employed for data analysis.
Results: The statistical analysis revealed no significant difference in WMS-R subtest and index scores between the drug and control groups at the 4-week and 12-week follow-up periods. However, within the drug group, there was a notable increase in the visual reproduction I and verbal paired associates II subtests during the specified time intervals.
Conclusion: While donepezil 5 mg did not exhibit a significant overall increase in memory scales compared to the control group over time, our findings suggest that this medication may exert a positive effect on specific memory subtests. Further research and exploration are warranted to better understand the potential benefits of donepezil in managing post-COVID-related memory impairment.
Trial registration: The study was approved by the Research Ethics Committee of Aja University of Medical Sciences (Approval ID: IR.AJAUMS.REC.1400.125) and registered in the Iranian Registry of Clinical Trials (IRCT) (Approval ID: IRCT20210816052203N1).
Keywords: Cognitive impairment; Donepezil Hydrochloride; Long-COVID; Memory Deficit; Post-acuteCOVIDsyndrome.